Skip to main content

Table 4 Trials Testing Preoperative Celecoxib in Esophageal Cancer

From: Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer

Study

Phase

Regimen

Patients

Conclusion

Dawson et al. [33]

1

5-FU/Cisplatin Chemoradiation Combined with Celecoxib

13

Regimen was well tolerated. The study was closed early because of external safety concerns regarding Celecoxib.

Altorki et al. [31]

2

Carboplatin/Paclitaxel Chemotherapy Combined with Celecoxib

39

Regimen was well tolerated with the exception of the fact that the rate perioperative venous thromboembolic events was higher than expected. Patients with tumors that expressed COX2 demonstrated higher rates of major pathological response and improved overall survival.

Govindan et al. [32]

2

5-FU/Cisplatin Chemoradiation Combined with Celecoxib

31

Regimen was well tolerated. The pathological complete response rate of 5-FU/Cisplatin/Celecoxib chemoradiation was similar to historical controls.